<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714621</url>
  </required_header>
  <id_info>
    <org_study_id>15/WM/0470 CCR4360</org_study_id>
    <nct_id>NCT02714621</nct_id>
  </id_info>
  <brief_title>MR-HIFU for Recurrent Gynaecological Cancer</brief_title>
  <acronym>HIFU-Gynae</acronym>
  <official_title>Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU): A Feasibility Study for Treating Recurrent Gynaecological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Cancer Research, United Kingdom</source>
  <brief_summary>
    <textblock>
      The primary objective of this pilot study is to determine whether or not it is feasible to
      use MRgHIFU to treat symptomatic (pain, bleeding) recurrent pelvic malignancy with an
      acceptable safety profile when conventional treatment options are not available. The ultimate
      goal is to be able not only to offer a viable method of symptom palliation in patients with
      recurrent pelvic tumours and improve their quality of life; but also to control tumour growth
      and extend life in a group of relatively young patients with isolated local recurrence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in pain, measured using a patient diary</measure>
    <time_frame>7 days post-treatment, follow up at 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in bleeding, measured using a questionnaire</measure>
    <time_frame>7 days post-treatment, follow up at 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Uterine Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <arm_group>
    <arm_group_label>Feasibility of MR-HIFU for painful gynaecological metastases</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Investigating whether it would be possible to use the MRgHIFU system to treat recurrent gynaecological cancers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment using MR-HIFU of painful gynaecological metastases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testing whether MRgHIFU could be an effective treatment for the symptoms of recurrent gynaecological cancers (pain and bleeding)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)</intervention_name>
    <arm_group_label>Treatment using MR-HIFU of painful gynaecological metastases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with recurrent pelvic gynaecological malignancy (cervix and endometrial
             cancer).

          -  Recurrent lesion is painful (NRS&gt;4) and not suitable for alternative treatments

          -  Intended target volume accessible for MRgHIFU treatment

          -  Intended target volume visible on noncontrast MR imaging

          -  Distance between target and skin ≥1cm

        Exclusion Criteria:

          -  MRI contraindicated (e.g. by incompatible metal implants or claustrophobia)

          -  Pregnancy

          -  Sedation contraindicated

          -  MRI contrast agent contraindicated

          -  Scar, internal or external fixation device along the beam path or at the target
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sharon Giles, MSc</last_name>
    <phone>0208 915 6493</phone>
    <email>sharon.giles@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nandita deSouza, Professor</last_name>
    <phone>0208 661 3289</phone>
    <email>nandita.desouza@icr.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Giles</last_name>
      <phone>02089156493</phone>
      <email>Sharon.Giles@rmh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Cancer Research, United Kingdom</investigator_affiliation>
    <investigator_full_name>NdeSouza</investigator_full_name>
    <investigator_title>Professor of Translational Imaging</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging (MRI)</keyword>
  <keyword>High Intensity Focused Ultrasound (HIFU)</keyword>
  <keyword>Focused Ultrasound Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

